Actively Recruiting
Study Comparing Electrochemotherapy Using Bleomycin Plus Carboplatin Versus Bleomycin Alone in Women With Relapsed Vulvar Cancer
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2022-05-27
92
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
This research evaluates treatments for women with vulvar cancer who have undergone multiple therapies like surgery and radiation or who cannot receive standard treatments. The study compares two approaches electroporation combined with the chemotherapy drugs Bleomycin and Carboplatin versus Bleomycin alone. Researchers aim to assess local progression-free survival, overall survival, quality of life, side effects, complications, and cost-effectiveness between these two treatment groups. Participants will receive either Bleomycin with Carboplatin or Bleomycin alone, both combined with electroporation. The study is randomized and follows patients over a period of five years to monitor outcomes. Treatments are administered as per protocol, and patients are carefully observed throughout the trial. During the study, participants will undergo various assessments including questionnaires to measure quality of life FACT-V, FACT-PAL, EQ-5D-5L, monitoring of adverse events, and tests to evaluate disease progression and survival outcomes. Blood tests and other laboratory evaluations will be performed to ensure safety and eligibility. The total follow-up period for each participant is five years, during which researchers will collect comprehensive data to compare the treatments.
CONDITIONS
Brief Title
Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer
Research Team
A
Anna Myriam Perrone, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here